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Background: Cyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for
older patients with early-stage breast cancer due to perceived superior tolerability. We sought to measure persistence
with CMF, adherence to oral cyclophosphamide, and the association of these with toxic effects.
Patients and methods: CALGB 49907 was a randomized trial comparing standard chemotherapy (CMF or AC,
provider/patient choice) with capecitabine in patients aged ≥65 with stage I–IIIB breast cancer. Those randomized to
standard therapy and choosing CMF were prescribed oral cyclophosphamide 100 mg/m2 for 14 consecutive days in
six 28-day cycles. Persistence was defined as being prescribed six cycles of at least one of the three CMF drugs.
Adherence was the number of cyclophosphamide doses that women reported they had taken divided by the number
prescribed. Persistence and adherence were based on case report forms and medication calendars.
Results: Of 317 randomized to standard chemotherapy, 133 received CMF. Median age was 73 (range 65–88).
Seventy-one percent submitted at least one medication calendar; 65% persisted with CMF. Non-persistence was
associated with node negativity (P = 0.019), febrile neutropenia (P = 0.002), and fatigue (P = 0.044). Average adherence
was 97% during prescribed cycles.
Conclusions: Self-reported adherence to cyclophosphamide was high, but persistence was lower, which may be
attributable to toxic effects.
Key words: antineoplastic combined chemotherapy protocols, breast neoplasms, geriatrics, medication adherence,
patient compliance, toxicity
introduction
Non-persistence with and non-adherence to oral antineoplastic
therapy may reduce the efficacy of oncologic treatment.
Persistence is defined by the International Society for
Pharmacoeconomics and Outcome Research (ISPOR) as the
duration of time from initiation to discontinuation of therapy
[1]. Optimal persistence occurs when a person keeps taking the
medication until the end of the prescribed course. In contrast,
ISPOR defines adherence as conforming to provider
recommendations with respect to the timing, dosage, and
frequency of medication taking [1]. Optimal adherence occurs
when no doses are skipped, doubled, or taken at the wrong
time or dosage.
Medication calendars are one method that can be used to
enhance adherence by reminding patients to take oral drugs at
home [2]. However, the efficacy of calendars is limited [3]. The
data from these calendars, particularly on clinical trials, can
also be utilized to provide information about persistence with
and adherence to a therapy. Knowledge of patient persistence
with and adherence to an intervention on a clinical trial is
critical to the interpretation of the results of the study,
including both therapeutic effect and toxic effects. Non-
persistence or non-adherence could lead investigators to
wrongly conclude that an effective drug was not beneficial, or
that a toxic drug was non-toxic. The public health implications
of either misassumption could be detrimental. Previous
research has suggested that older age, in particular, is a risk
factor for non-adherence to adjuvant hormonal therapy for
breast cancer [4–6]. In this study, we sought to evaluate
persistence with adjuvant cyclophosphamide-methotrexate-5-
fluorouracil (CMF) and adherence to the oral component of
the regimen in a multicenter study of older women with breast
cancer.
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methods
The Cancer and Leukemia Group B (CALGB) led a randomized trial in
women with early-stage breast cancer aged 65 years and older to compare
the efficacy of (i) six cycles of standard chemotherapy with CMF (oral
cyclophosphamide 100 mg/m2 for 14 consecutive days, intravenous
methotrexate 40 mg/m2 on days 1 and 8, and intravenous 5-fluorouracil
600 mg/m2 on days 1 and 8, in six 28-day cycles) or doxorubicin and
cyclophosphamide (AC) with (ii) six cycles of experimental chemotherapy
with the oral 5-fluorouracil pro-drug capecitabine [7]. Patients with stage
I–IIIB breast cancer were randomized to standard chemotherapy or
capecitabine, and the primary trial end point was relapse-free survival.
Women who received capecitabine were offered participation in an
adherence substudy using microelectronic monitoring system (MEMS) caps
[8]. Women who chose to receive CMF were prescribed oral
cyclophosphamide, and were asked to use printed medication calendars to
record the days that they took doses of cyclophosphamide. Although
funding did not allow for the use of MEMS caps or other adherence
measures among the women receiving CMF, medication calendars were
used to evaluate adherence in this group. Persistence data were collected
through standard case report forms (CRFs) submitted by the study-site
investigators on each patient. Toxic effects were reported based on the NCI
CTCAE version 2. We sought to evaluate persistence, adherence, and their
association with toxic effects in patients who received CMF in this study.
study subjects
Participants in the randomized controlled trial, CALGB 49907, have been
described in detail previously [7]. These were women 65 years of age or
older with operable stage I–IIIB breast cancers and a performance status of
0 to 2 (according to the National Cancer Institute criteria). Patients had to
have an expected survival of more than 5 years and no medical condition
that would make treatment with chemotherapy unreasonably hazardous.
Women with any other active cancer or a previous cancer with a risk of
relapse that >30% were excluded. Each participant signed an IRB-approved,
protocol-specific informed consent for CALGB 49907 in accordance with
federal and institutional guidelines. For the present analysis, only patients
assigned to standard therapy and choosing to receive CMF instead of AC
were included.
definitions
Persistence with CMF was defined as being prescribed all six cycles of at
least one of the three CMF drugs. Adherence to oral cyclophosphamide
was calculated as the number of cyclophosphamide doses that women
reported they had taken according to patient medication calendars divided
by the number of doses they were prescribed. Adherence was calculated for
each cycle (28 days) for which a participant submitted a medication
calendar. If no calendar was submitted for a cycle, this was considered
missing data and not included in adherence analyses. Overall adherence
was the averaged proportion of pills taken for all participants for the cycles
for which medication calendars were submitted for the days up until the
day each patient was told to stop taking the drugs (based on CRFs) either
because of completion of therapy or because of a clinical decision to stop
therapy before completion.
Consistent with prior literature, we defined a participant as non-
adherent if <80% of the cyclophosphamide doses expected (between the
time she began and the time she stopped treatment) were recorded in the
cycles for which she submitted calendars [2]. Because each cycle should
have included 14 consecutive daily doses of cyclophosphamide, non-
adherence in a particular cycle was defined as report of 11 or fewer doses
taken. When analyzing adherence over the whole study, the number of
doses that qualified as non-adherent varied by individual, depending on
the number of cycles over which a patient persisted with treatment and the
number of calendars she submitted.
statistical methods
Patient registration, randomization, and data collection were managed by
the CALGB Statistical Center. Data quality was insured by review of data
by CALGB Statistical Center staff and by the study chairperson. Statistical
analyses were carried out CALGB statisticians using the SAS® software,
version 9.2.
Patient characteristics of interest include age (continuous), tumor size
(continuous), race (white versus other), ethnicity (Hispanic versus Non-
Hispanic), ECOG performance status (normal, ambulatory, >50% time in
bed), type of primary surgery (mastectomy versus lumpectomy), estrogen
receptor status (negative versus positive), progesterone receptor status
(negative versus positive), and lymph node status (negative versus positive).
Adverse event (AE) categories of interest were selected as any AE of grade
3 or 4 severity possibly, probably, or definitely related to CMF for which
five or more patients experienced the AE. AE categories include diarrhea,
fatigue, febrile neutropenia, leukopenia, nausea, thrombocytopenia,
thromboembolism, and vomiting. Each AE category was analyzed as a
dichotomous variable.
Group comparisons between treatment regimens within the standard
arm (CMF versus AC) were carried out using a Wilcoxon rank-sum test for
continuous variables and Fisher’s exact test for categorical variables.
Similarly, comparisons were carried out between persistent and non-
persistent groups, using a Wilcoxon rank-sum test for continuous variables
and Fisher’s exact test for categorical variables. Univariate logistic
regression modeling was used to identify marginally significant (P≤ 0.2)
predictors for persistence. The significant univariate predictors were then
used as candidate variables in building a multivariable logistic regression
model with a forward stepwise selection. Odds ratios with corresponding
95% confidence intervals were taken from respective logistic models. This
procedure was completed twice; first time with independent variables
limited to patient characteristics and a second time with independent
variables limited to AE categories. Fisher’s exact tests were used to compare
patient characteristics based on the occurrence of AEs. Descriptive statistics
were used to summarize patient characteristics and AEs among the
adherent and non-adherent patients.
As part of the quality assurance program of the CALGB, members of the
Audit Committee visit all participating institutions at least once every 3
years to review source documents. The auditors verify compliance with
federal regulations and protocol requirements. Such on-site review of
medical records was carried out for a subgroup of 153 patients (24%) of
the 633 patients in CALGB 49907.
results
CALGB 49907 opened in 2001 and closed in November 2006,
when a pre-planned boundary for futility was crossed. This
occurred after the first planned analysis of 600 patients showed
that patients randomized to capecitabine were two times more
likely to relapse (P = 0.0006) and almost two times more likely
to die (P = 0.019) than patients assigned to standard (CMF or
AC) therapy [7]. When the study closed, 633 patients had been
accrued to the clinical trial, 326 of whom had been
randomized to standard therapy. Nine patients withdrew
before they chose a regimen on the standard care arm. One
hundred and thirty-three of these 326 women elected to
receive CMF rather than AC on the standard arm. The flow
diagram of the patient selection process is presented in
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Figure 1. Patient characteristics of those who chose to receive
CMF or AC are presented in Table 1. The median age of CMF
patients was 73 (range 65–88). CMF patients were older
(P = 0.008) and less likely to be Hispanic (P < 0.001) than AC
patients.
persistence with cyclophosphamide
Eighty-six patients (65%) persisted with CMF to the
completion of planned protocol therapy. Characteristics of
persistent versus non-persistent patients are presented in
supplementary Table S1, available at Annals of Oncology
online. Two of these 86 had stopped cyclophosphamide but
continued on methotrexate and 5-fluorouracil for six cycles,
and the rest received all three drugs to completion. In a
multivariable logistic regression model (presented in Table 2),
non-persistence was associated with lymph node negativity
(P = 0.016) and hormone receptor-positive tumors (P = 0.014).
In a multivariable logistic regression model focusing on grade
3 and 4 toxic effects as independent variables, non-persistence
was significantly associated with the report of fatigue
(P = 0.025) and febrile neutropenia (P = 0.003), but not with
any other grade 3 or 4 AE (Table 3). By univariate testing,
using CTCAE v.2, no patient or tumor characteristic was found
to be associated with a grade 3 or 4 AE.
Out of the 19 non-persistent patients whose non-persistence
was attributed to the toxicity of the treatment, 8 patients
experienced three or more different types of grade 3 or 4 AE
that were thought to be possibly, probably, or definitely related
to CMF over the course of treatment. The grade 3 and 4 AEs
that were documented as possibly, probably, or definitely related
to CMF in these 19 patients included the following (with the
number experiencing each toxicity during the course of
treatment in parentheses): pain (1), diarrhea (3), nausea (3),
fever (1), vomiting (3), neutropenia/leukopenia (14),
thromboembolism (1), coagulopathy (1), febrile neutropenia/
neutropenic infection (5), infection with normal neutrophil
count (1), thrombocytopenia (1), renal insufficiency (2), syncope
(2), ataxia (2), speech impairment (1), fatigue (3), dehydration
(1), hypokalemia (1), hypotension (2), hyperglycemia (1) and
anemia (1). Statistical testing was not carried out on this subset
of 19 patients due to small sample size.
adherence to cyclophosphamide
Ninety-four of 133 (71%) CMF-treated patients submitted at
least one medication calendar documenting their use of
cyclophosphamide. Fewer calendars were submitted in later
treatment cycles (supplementary Table S2, available at Annals
of Oncology online). There were no obvious differences in
reasons for treatment discontinuation between those who did
and did not submit calendars (supplementary Table S3,
available at Annals of Oncology online). Average adherence
across all cycles with available data was 97%. Five percent (five
women) reported taking <80% of total expected doses (number
of observed doses/number of expected doses <0.80) and were
therefore considered non-adherent. Since a small number of
patients were observed in the non-adherent group, there was
limited statistical power to identify associations with patient
and tumor characteristics (Table 4).
Figure 1 Flow diagram of participants.
Table 1. Baseline participant demographic and clinical characteristics for
patients who received CMF compared with AC
Characteristic CMF (n = 133) AC (n = 184) P-valuea
Median age, years 73.4 71.7 0.008*
Median tumor size, cm 2.00 2.20 0.724
Race
White 116 (87%) 155 (84%)
Other 17 (13%) 29 (16%) 0.520
Ethnicity
Hispanic or Latino 0 14 (8%)
Non-Hispanic 133 (100%) 170 (92%) <0.001*
ECOG performance status
0 100 (75%) 134 (73%)
1 29 (22%) 48 (26%)
2 4 (3%) 2 (1%) 0.344
Most extensive primary surgeryb
Lumpectomy 62 (47%) 88 (48%)
Mastectomy 71 (53%) 94 (52%) 0.820
Hormone receptor status
Negative 43 (32%) 60 (33%)
Positive 90 (68%) 123 (67%) 1.000
Lymph node status
Negative 31 (23%) 59 (32%)
Positive 102 (77%) 124 (67%) 0.101
aFisher’s exact test for categorical variables, Wilcoxon’s rank-sum test for
continuous variables.
bPrimary surgery type was not reported for two patients.
*P-value <0.05.
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discussion
Non-persistence and non-adherence may impair the efficacy of
oral oncologic therapies. In recent years, attention has focused
on improving the way that oral therapies are ordered,
dispensed, administered, and monitored in an effort to
improve the quality of cancer care [9]. In clinical trials, it has
been recognized that differences in adherence rates between
two regimens may impact results, so medication calendars have
conventionally been used as a convenient method to measure
and promote adherence. In women with breast cancer,
persistence with and adherence to oral adjuvant hormonal
therapy have been shown to affect a variety of outcomes,
including survival [4, 5, 10–15]. However, less is known about
persistence with and adherence to oral chemotherapy regimens
for this disease. In one study, Mayer et al. showed that more
than a third of patients were over-adherent (i.e. took more
than their prescribed doses) to capecitabine and gefitinib in a
phase I metastatic breast cancer trial, but there were too few
participants to evaluate for an impact on outcomes [16].
Furthermore, patients with metastatic disease may be more
motivated to take their oral antineoplastics agents than early-
stage patients, so it is important to also study patients without
advanced disease.
In the current study, there were too few women on CMF to
have adequate power to detect a difference in disease outcomes
based on adherence or persistence, but one prior study did
suggest that there may be a dose effect for CMF (i.e. patients
who take fewer cycles obtain less benefit from the treatment)
[17]. Also, the results of C49907 showed that standard
chemotherapy reduced risk even in this older population,
suggesting that non-persistent and non-adherent patients may
be more likely to experience recurrence.
Table 3. Logistic regression modeling predicting persistence with grade 3–4 adverse event covariates
Univariate logistic regression models
Effect Description Odds ratio 95% confidence interval P-value
Leukopenia No leukopenia versus leukopenia 1.24 0.60–2.56 0.569
Thrombocytopenia No thrombocytopenia versus thrombocytopenia 1.26 0.20–7.81 0.806
Fatigue No fatigue versus fatigue 4.50 1.44–14.11 0.010*
Nausea No nausea versus nausea 4.15 0.99–17.45 0.052
Vomiting No vomiting versus vomiting 3.37 0.77–14.81 0.107
Diarrhea No diarrhea versus Diarrhea 3.08 0.82–11.52 0.095
Febrile neutropenia No febrile neutropenia versus febrile neutropenia 23.61 2.91–191.32 0.003*
Thromboembolism No thromboembolism versus Thromboembolism 0.36 0.04–3.19 0.358
Multivariable logistic regression model (entry P-value = 0.2, keep P-value = 0.2)
Effect Description Odds ratio 95% confidence interval Adjusted P-value
Fatigue No fatigue versus Fatigue 4.08 1.20–13.91 0.025*
Vomiting No vomiting versus Vomiting 4.53 0.99–20.64 0.051
Febrile neutropenia No febrile neutropenia versus febrile neutropenia 24.34 2.93–201.94 0.003*
*P-value <0.05.
Table 2. Logistic regression modeling predicting persistence with patient characteristic covariates
Univariate logistic regression models
Effect Description Odds ratio 95% confidence interval P-value
Age Five-year increments 1.28 0.87–1.88 0.212
Performance status 0 versus 2 0.16 0.02–1.64 0.117
1 versus 2 0.20 0.02–2.21 0.327
Node status Negative versus positive 2.05 0.90–4.65 0.086
Surgery Mastectomy versus lumpectomy 0.99 0.49–2.02 0.974
Hormone receptor status Negative versus positive 0.43 0.19–0.99 0.047*
Race Other versus white 1.33 0.47–3.76 0.591
Multivariable logistic regression model (entry P-value = 0.2, keep P-value = 0.2)
Effect Description Odds ratio 95% confidence interval Adjusted P-value
Node status Negative versus positive 3.12 1.24–7.84 0.016*
Hormone receptor status Negative versus positive 3.17 1.27–7.94 0.014*
*P-value <0.05.
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It is informative to compare our findings with those of our
analysis of adherence to capecitabine using MEMS caps in this
trial, in which adherence to capecitabine averaged 78%, and
25% of patients took <80% of prescribed capecitabine doses.6
Self-reported measures of adherence generally over-estimate
adherence compared with more objective measures (e.g.
MEMS caps) [18, 19]. Thus, it is unclear whether adherence to
capecitabine in this study was actually less than adherence to
the oral component of CMF. Because patients who did not
turn in medication calendars may have been less adherent to
the oral component of CMF, this present analysis likely over-
estimates adherence in the CMF arm.
In this analysis, there were few identifiable demographic and
clinical predictors of persistence and adherence. The
association between non-persistence and both node-negativity
and hormone receptor-positive tumors suggests that those
predicted to have less benefit from chemotherapy (because of
lower risk and less chemo-sensitive disease, respectively) may
have been less likely to be persistent. This is consistent with
prior data suggesting that beliefs about the efficacy of a
medication may impact medication-taking behaviors [2]. The
association between certain toxic effects and non-persistence is
likewise an expected but still important finding from this study.
Elderly patients may be particularly susceptible to side-effects
from chemotherapy that lead to treatment cessation. Bone
marrow reserve may be less robust in older patients, and
energy levels may be more tenuous. In patients of any age,
experiences such as hospital admission for febrile neutropenia
may be unpleasant and/or frightening enough to dissuade
them from proceeding with the planned oncologic
treatment.
Consistent with capecitabine adherence in this study,
adherence to cyclophosphamide was not associated with age in
women aged 65 or older at diagnosis [8]. However, because
non-adherence was rare, the power was limited for analyses
focused on adherence. Specific concomitant medication data
were not available for our analyses, but poly-pharmacy may
have contributed to non-adherence and non-persistence.
Future work is warranted to evaluate the effects of age on
persistence with and adherence to oral chemotherapy in a
population of women including both older and younger
women, as well as to explore other factors that may be
associated with oral chemotherapy persistence or adherence
(including the psychosocial state of the patient, intentions to
adhere, and treatment-related factors) [2, 20].
The results from this study must be interpreted in light of its
limitations. Self-reported adherence measures can be inaccurate
and may over-estimate adherence as noted above. Further, data
collected on this study did not include the timing of doses of
cyclophosphamide, just the total number per cycle, so we were
not able to assess for the proportion of doses that were taken
too close together or too far apart. Finally, adherence in the
setting of this trial may not reflect persistence with and
adherence to CMF in the community both because the
knowledge among participants that adherence was being
monitored using the medication calendars may have improved
adherence with cyclophosphamide among some women and
because participants in a clinical trial may be different from
those who either opt not to or never have the option to
participate [21, 22]. In this study, as usual in clinical trials,
comorbidities were minimal at the time of enrollment (partly
due to exclusion criteria). Therefore, persistence and adherence
may be higher than in the real world, where elderly patients
with multiple comorbidities are often prescribed CMF when
chemotherapy for early-stage breast cancer is warranted.
Further research to evaluate the adherence to and persistence
with oral chemotherapies using potentially more sensitive and
less subjective methods in non-trial populations is clearly
warranted.
Still, our findings have important implications for the
treatment of older women with early-stage breast cancer with
adjuvant oral CMF and future research using oral medications
in oncology. The decision to treat an older woman with CMF
should take into consideration the substantial rate of non-
persistence seen in this study. Monitoring for and
interventions to prevent febrile neutropenia and fatigue, in
particular, may help to improve persistence. CMF using
intravenous cyclophosphamide is an alternative regimen for
which concerns about adherence would be minimized and
tolerability may be better, allowing for improved persistence.
Table 4. Adherent versus non-adherent patients
Adherent Non-adherent
Characteristic n = 89 (95%) n = 5 (5%)
Median age (years) 73.5 75.8
Median tumor (cm) 2.00 1.70
Race
White 78 (88%) 4 (80%)
Other 11 (12%) 1 (20%)
Ethnicity
Hispanic 0 0
Non-Hispanic 89 (100%) 5 (100%)
ECOG performance status
0 68 (76%) 3 (60%)
1 20 (22%) 2 (40%)
2 1 (1%) 0
Most extensive primary surgery
Lumpectomy 43 (48%) 3 (60%)
Mastectomy 46 (52%) 2 (40%)
Hormone receptor status
Positive 53 (60%) 5 (100%)
Negative 36 (40%) 0
Lymph node status
Positive 68 (76%) 5 (100%)
Negative 21 (24%) 0
Grade 3 or 4 adverse eventsb
Neutropenia 25 (28%) 0
Leukopenia 33 (37%) 3 (60%)
Fatigue 11 (12%) 1 (20%)
Nausea 4 (4%) 1 (20%)
Diarrhea 6 (7%) 1 (20%)
Febrile neutropenia 7 (8%) 1 (20%)
Thromboembolism 5 (6%) 0
aA progesterone receptor status was not provided for one patient in the
non-adherent group.
bAdditional grade 3 or 4 adverse events reported in less than five patients:
anemia, thrombocytopenia, mucositis and vomiting.
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However, there are limited data regarding the efficacy of this
regimen compared with the well-studied oral
cyclophosphamide CMF regimen [23]. Future cancer clinical
trials evaluating oral agents should closely measure, monitor,
and promote adherence to optimize the understanding of the
benefits and risks of the treatment. Additional evaluation of
adherence to and persistence with oral chemotherapy outside
of the clinical trial setting is clearly warranted.
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